BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16969286)

  • 1. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Uderzo C; Bonanomi S; Busca A; Renoldi M; Ferrari P; Iacobelli M; Morreale G; Lanino E; Annaloro C; Volpe AD; Alessandrino P; Longoni D; Locatelli F; Sangalli H; Rovelli A
    Transplantation; 2006 Sep; 82(5):638-44. PubMed ID: 16969286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.
    Shimoni A; Yeshurun M; Hardan I; Avigdor A; Ben-Bassat I; Nagler A
    Biol Blood Marrow Transplant; 2004 Jul; 10(7):484-93. PubMed ID: 15205669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
    Willems E; Baron F; Seidel L; Frère P; Fillet G; Beguin Y
    Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
    Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation.
    Diaz MA; Vicent MG; Prudencio M; Rodriguez F; Marin C; Serrano A; Sevilla J; Casado J; Madero L
    Haematologica; 2002 Mar; 87(3):292-8. PubMed ID: 11869942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy in transplantation and malignancy.
    Qu L; Kiss JE
    Semin Thromb Hemost; 2005 Dec; 31(6):691-9. PubMed ID: 16388420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001).
    Safdar A; Singhal S; Mehta J
    Cancer; 2004 Jun; 100(11):2456-61. PubMed ID: 15160352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties.
    Uderzo C; Pillon M; Corti P; Tridello G; Tana F; Zintl F; Nysom K; Galambrun C; Fagioli F; Varotto S; Messina C; Verdeguer A; Urban C; Faraci M; Dini G; Fedeli S; Tichelli A; Rovelli A; Socié G
    Bone Marrow Transplant; 2007 Jun; 39(11):667-75. PubMed ID: 17401396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.
    Cho BS; Yahng SA; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Transplantation; 2010 Oct; 90(8):918-26. PubMed ID: 20717073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Cho BS; Min CK; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim Y; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2008 May; 41(9):813-20. PubMed ID: 18209725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.